Accrued Liabilities - Skye Bioscience Inc (NASDAQ:SKYE) - Alpha Spread

Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.49 USD 4.77% Market Closed
Market Cap: 154.1m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Skye Bioscience Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Skye Bioscience Inc
Accrued Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Skye Bioscience Inc
NASDAQ:SKYE
Accrued Liabilities
$2.1m
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
$5.2B
CAGR 3-Years
-9%
CAGR 5-Years
-4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$13.7B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$2.9B
CAGR 3-Years
26%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.4B
CAGR 3-Years
5%
CAGR 5-Years
22%
CAGR 10-Years
26%

See Also

What is Skye Bioscience Inc's Accrued Liabilities?
Accrued Liabilities
2.1m USD

Based on the financial report for Jun 30, 2024, Skye Bioscience Inc's Accrued Liabilities amounts to 2.1m USD.

What is Skye Bioscience Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
120%

Over the last year, the Accrued Liabilities growth was 17%. The average annual Accrued Liabilities growth rates for Skye Bioscience Inc have been 120% over the past three years .

Back to Top